Volume 11, Issue 2 pp. 180-186

Bone marrow transplantation in children with severe aplastic anemia using a conditioning regimen containing 3 Gy of total body irradiation, cyclophosphamide with or without antithymocyte globulin

Jiro Inagaki

Jiro Inagaki

Section of Pediatrics, National Kyusyu Cancer Center, Fukuoka

Search for more papers by this author
Yoshihisa Nagatoshi

Yoshihisa Nagatoshi

Section of Pediatrics, National Kyusyu Cancer Center, Fukuoka

Search for more papers by this author
Yoshifumi Kawano

Yoshifumi Kawano

Section of Pediatrics, National Kyusyu Cancer Center, Fukuoka

Department of Pediatrics, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima

Search for more papers by this author
Yusuke Saito

Yusuke Saito

Section of Pediatrics, National Kyusyu Cancer Center, Fukuoka

Search for more papers by this author
Daijiro Takahashi

Daijiro Takahashi

Section of Pediatrics, National Kyusyu Cancer Center, Fukuoka

Search for more papers by this author
Jun Nagayama

Jun Nagayama

Section of Pediatrics, National Kyusyu Cancer Center, Fukuoka

Search for more papers by this author
Yuichi Shinkoda

Yuichi Shinkoda

Section of Pediatrics, National Kyusyu Cancer Center, Fukuoka

Search for more papers by this author
Hideki Hirata

Hideki Hirata

Section of Radiology, National Kyusyu Cancer Center

Search for more papers by this author
Jun Okamura

Jun Okamura

Institute for Clinical Research, National Kyusyu Cancer Center, Fukuoka, Japan

Search for more papers by this author
First published: 27 November 2006
Citations: 4
Jiro Inagaki, Section of Pediatrics, National Kyusyu Cancer Center 3-1-1, Notame, Minami-ku, Fukuoka 811-1395, Japan
Tel.: +81 92 541 3231
Fax: +81 92 542 8503
E-mail: [email protected]

Abstract

Abstract: We have employed the 3 Gy toal body irradiation (TBI) containing conditioning regimen to bone marrow transplantation (BMT) for severe aplastic anemia (SAA) in pediatric patients irrespective of donor type since March 1986. The outcome of BMT for 17 SAA patients is favorable. Eight patients received BMT from human leukocyte antigen matched-related donors (MRD) and nine received BMT from alternative donors. The conditioning regimen consisted of 3-Gy TBI and cyclophosphamide of 200 mg/kg in the BMT from MRD. In the case of BMT from alternative donor, antithymocyte globulin 10 mg/kg was added to the regimen. Fifteen of 17 patients (88%) engrafted on median of day 18 (range, 11–26) and all 13 evaluable patients showed complete donor chimerism by median 30 (range, 13–47) days after BMT. Fourteen patients have survived with a median follow-up of 67 (range, 2–228) months and the probability of survival was 81.9% (95% CI, 63.3–100%). No late complications including second malignancies caused by TBI have been observed and all three female patients have regular menstruation. In conclusion, TBI of 3 Gy appears to be an appropriate dose regarding to ensure engraftment and avoid the risk of late adverse event for SAA patients.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.